Clinical outcomes of cessation of nucleoside/nucleotide analogues in Chinese patients with HBeAg-negative chronic hepatitis B  

作　　者：Fengyi Li Yadong Zhang Chao Liu Juan Li Dali Zhang Yinjie Gao 

机构地区：[1]Department of Hepatology,The Fifth Medical Center of Chinese People's Liberation Army General Hospital,Beijing 100039,China [2]Health Center of Armed Police Supervision,Daxing District,Beijing 102607,China

出　　处：《iLIVER》2024年第2期22-27,共6页国际肝胆健康（英文）

基　　金：supported by the Beijing Municipal Foundation for Clinical Research[Z181100001718033];the Project for Prevention and Treatment of AIDS and Viral Hepatitis[2018ZX10301-404];the National Major Science and Technology Project of China[2019YFC0840704].

摘　　要：Background and aims:Cessation of nucleoside/nucleotide analogue(Nuc)therapy in patients with HBeAg-negative chronic hepatitis B(CHB)remains controversial.Methods:In this prospective,single-center cohort study,we recruited 45 patients with HBeAg-negative CHB from The Fifth Medical Center of Chinese People's Liberation Army General Hospital in China's Mainland.Patients were classified into a Nuc cessation group(n?27)and Nuc continuation group(n?18)and followed-up for 36 months.Nuc were stopped after being inactive for at least 4 years(normal alanine aminotransferase(ALT),undetectable hepatitis B virus(HBV)DNA),with liver fibrosisStage1(S1)and inflammationGrade(G1).Results:Within 3 years of follow-up,51.9%patients with Nuc cessation had virological relapse and 14.8%had ALT elevation,while all patients with Nuc continuation had undetectable HBV DNA and normal ALT.The rate of HBsAg loss after Nuc cessation was 22.2%compared with no seroconversion in patients with Nuc continuation.The hepatitis flare rate was 11.1%and there were no cases of hepatic decompensation after Nuc cessation.End of treatment(EOT)HBsAg,HBV RNA,and decline in HBV core-related antigen(HBcrAg)rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.Conclusion:This study showed favorable HBsAg loss and low hepatitis flare rates after Nuc cessation.EOT HBsAg,HBV RNA,and decline in HBcrAg rate were predictive markers for HBsAg seroconversion at 6 months post-Nuc cessation.

关 键 词：Nucleoside analogues Nucleotide analogues Therapy cessation HBeAg-negative Clinical relapse 

分 类 号：R512.62[医药卫生—内科学]